TLR7 and acute myeloid leukemia: Furthermore, it appeared as if cytogenetics correlated with R848 (TLR7/8 agonist) response: 23/45 patients (45%) with normal or favorable (i.e., core-binding factor AML) karyotype responded with increased cytokine secretion upon R848 stimulation as opposed to 7/28 patients (25%) with an intermediate or adverse karyotype (Fisher’s exact test, p = 0.010).